Trending Now
Vistagen Therapeutics Inc (NASDAQ: VTGN) Reports Revenues Of $1.1 Million From...
Vistagen Therapeutics Inc (NASDAQ: VTGN) posted revenues of $1.1 million in 2021 from its sublicense revenues related to the non-dilutive upfront payment of $5.0...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Verastem Oncology (NASDAQ:VSTM) Commence Phase 2 VS-6766 Study in Low-Grade Serous...
Verastem Oncology (NASDAQ:VSTM) has announced the commencement of phase 2 registration-focused clinical study of its RAF/MEK inhibitor, VS-6766, and its FAK inhibitor, defactinib, in...
MAKE IT MODERN
LATEST REVIEWS
Tonix Pharmaceuticals Holding Corp’s (NASDAQ: TNXP) Oral Presentation Accepted At ACR...
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced the oral presentation's acceptance and information at the American College of Rheumatology Convergence 2021.
Tonix’s oral presentation...
MAKE IT MODERN
PERFORMANCE TRAINING
resTORbio Inc. (NASDAQ:TORC) To Initiate Study Evaluating Prophylaxis With RTB101 in Reducing COVID-19 Severity
resTORbio Inc. (NASDAQ:TORC) has initiated a randomized placebo-controlled double-blind study of RTB101, which is an orally-administered powerful small-molecule target inhibitor of rapamycin complex relative...
AlloVir’s (NASDAQ:ALVR) Receives IND Clearance For ALVR106 In Respiratory Disease and Infections
The US FDA has cleared AlloVir’s (NASDAQ:ALVR) Investigational New Drug (IND) application for ALVR106. ALVR106 is the company's off-the-shelf, allogeneic virus specific...
CEO And President Of AzurRx BioPharma Inc (NASDAQ:AZRX) Discuss Plans To Develop Optimized Formulations...
AzurRx BioPharma Inc (NASDAQ:AZRX)’s CEO - James Sapirstein, and CMO – James, featured in the conference call on March 31, 2021, discussed plans to...
Annovis Bio, Inc. (NYSE: ANVS) Surges 24% as Alzheimer’s Treatment Buntanetap Advances to Final Evaluation...
In an exciting development for both the medical community and investors, Annovis Bio, Inc. (NYSE: ANVS), a pioneer in the development...
iBio Inc. (NYSEAMERICAN: IBIO) Announces Fiscal Q1 2022 Financial Results and Partnership To Study...
iBio Inc. (NYSEAMERICAN: IBIO) has announced its Q1 2022 financial result and offered a corporate update. Revenues during the quarter dropped 49% YoY to...
MAKE IT MODERN
